scholarly journals MR guided high intensity focused ultrasound (MRgHIFU) for treating recurrent gynaecological tumours: a pilot feasibility study

2019 ◽  
pp. 20181037 ◽  
Author(s):  
Sharon L Giles ◽  
Georgios Imseeh ◽  
Ian Rivens ◽  
Gail R ter Haar ◽  
Alexandra Taylor ◽  
...  
Keyword(s):  
High Intensity ◽  
Focused Ultrasound ◽  
Organs At Risk ◽  
Symptom Relief ◽  
Tumour Volume ◽  
Target Volume ◽  
High Intensity Focused Ultrasound ◽  
Limiting Factors ◽  
Treatment Plans ◽  
Gynaecological Tumours

Objective: To assess the feasibility of targeting recurrent gynaecological tumours with MR guided high intensity focused ultrasound (MRgHIFU). Methods: 20 patients with recurrent gynaecological tumours were prospectively scanned on a Philips/Profound 3 T Achieva MR/ Sonalleve HIFU system. Gross tumour volume (GTV) and planning target volume (PTV) were delineated on T 2W and diffusion-weighted imaging (DWI). Achievable treatment volumes that (i) assumed bowel and/or urogenital tract preparation could be used to reduce risk of damage to organs-at-risk (TVoptimal), or (ii) assumed no preparations were possible (TVno-prep) were compared with PTV on virtual treatment plans. Patients were considered treatable if TVoptimal ≥ 50 % PTV. Results: 11/20 patients (55%) were treatable if preparation strategies were used: nine had central pelvic recurrences, two had tumours in metastatic locations. Treatable volume ranged from 3.4 to 90.3 ml, representing 70 ± 17 % of PTVs. Without preparation, 6/20 (30%) patients were treatable (four central recurrences, two metastatic lesions). Limiting factors were disease beyond reach of the HIFU transducer, and bone obstructing tumour access. DWI assisted tumour outlining, but differences from T 2W imaging in GTV size (16.9 ± 23.0%) and PTV location (3.8 ± 2.8 mm in phase-encode direction) limited its use for treatment planning. Conclusions: Despite variation in size and location within the pelvis, ≥ 50 % of tumour volumes were considered targetable in 55 % patients while avoiding adjacent critical structures. A prospective treatment study will assess safety and symptom relief in a second patient cohort. Advances in knowledge: Target size, location and access make MRgHIFU a viable treatment modality for treating symptomatic recurrent gynaecological tumours within the pelvis.

scholarly journals Novel Therapeutic Method for Unresectable Pancreatic Cancer-The Impact of the Long-Term Research in Therapeutic Effect of High-Intensity Focused Ultrasound (HIFU) Therapy

2021 ◽  
Vol 28 (6) ◽  
pp. 4845-4861
Author(s):  
Atsushi Sofuni ◽  
Yasutsugu Asai ◽  
Takayoshi Tsuchiya ◽  
Kentaro Ishii ◽  
Reina Tanaka ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Symptom Relief ◽  
Tumor Ablation ◽  
High Intensity Focused Ultrasound ◽  
Therapeutic Effects ◽  
Unresectable Pancreatic Cancer ◽  
Advanced Therapy ◽  
The Impact

High-intensity focused ultrasound (HIFU) is a novel advanced therapy for unresectable pancreatic cancer (PC). HIFU therapy with chemotherapy is being promoted as a novel method to control local advancement by tumor ablation. We evaluated the therapeutic effects of HIFU therapy in locally advanced and metastatic PC. PC patients were treated with HIFU as an optional local therapy and systemic chemotherapy. The FEP-BY02 (Yuande Bio-Medical Engineering) HIFU device was used under ultrasound guidance. Of 176 PC patients, 89 cases were Stage III and 87 were Stage IV. The rate of complete tumor ablation was 90.3%, while that of symptom relief was 63.8%. The effectiveness on the primary lesions were as follows: complete response (CR): n = 0, partial response (PR): n = 21, stable disease (SD): n = 105, and progressive disease (PD): n = 47; the primary disease control rate was 71.0%. Eight patients underwent surgery. The median survival time (MST) after diagnosis for HIFU with chemotherapy compared to chemotherapy alone (100 patients in our hospital) was 772.3 vs. 346.6 days (p < 0.001). Compared with chemotherapy alone, the combination of HIFU therapy and chemotherapy demonstrated significant prolongation of prognosis. This study suggests that HIFU therapy has the potential to be a novel combination therapy for unresectable PC.

High-intensity focused ultrasound (HIFU) for pancreatic carcinoma: evaluation of feasibility, reduction of tumour volume and pain intensity

2016 ◽  
Vol 26 (11) ◽  
pp. 4047-4056 ◽  
Author(s):  
Milka Marinova ◽  
Maximilian Rauch ◽  
Martin Mücke ◽  
Roman Rolke ◽  
Maria A. Gonzalez-Carmona ◽  
...  
Keyword(s):  
Pain Intensity ◽  
Pancreatic Carcinoma ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Tumour Volume ◽  
High Intensity Focused Ultrasound

scholarly journals Magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) hyperthermia for primary rectal cancer: A virtual feasibility analysis.

2019 ◽  
Vol 5 (suppl) ◽  
pp. 77-77
Author(s):  
Kaitlyn Perry ◽  
Robert Staruch ◽  
Samuel Pichardo ◽  
Yuexi Huang ◽  
Merrylee McGuffin ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Focused Ultrasound ◽  
Organs At Risk ◽  
Tumour Volume ◽  
High Intensity Focused Ultrasound ◽  
Beam Path ◽  
Invasive Treatment ◽  
Cancer Society ◽  
Average Width ◽  
Primary Rectal Cancer

77 Background: MR-HIFU Hyperthermia (HT) is a non-invasive treatment modality with real-time thermometry that ensures accurate and precise heating of a target with minimal effect on adjacent tissue. This energy deposition within a tumour can produce local bioeffects resulting in thermal chemo- and radiosensitization. MR-HIFU has been shown to be safe and feasible in a companion phase I study for recurrent rectal cancer. The purpose of this study is to determine the feasibility of MR-HIFU in treating primary rectal tumours. Methods: With ethics approval, the anatomic characteristics and surrounding structures of rectal tumours diagnosed at Sunnybrook from 2014-2019 were retrospectively analyzed. Three orthogonal views of MR images were used to determine the potential ultrasound (US) beam path and organs at risk (OAR). In part 2 of the study, the gross tumour volume was delineated for 30 rectal tumours (10 low, mid &high). Image datasets were imported into the Sonalleve MR-HIFU workstation for virtual treatment simulation and planning to determine tumour targetability, coverage, optimal patient set-up, and transducer positioning. Results: Of the 105 tumours analyzed, 36, 52, and 17 were low, mid, and high, respectively. The average width of the acoustic window (sciatic notch) for the US beam path was 5.8 ± 1.4cm, average tumour length was 5.24 ± 2.0cm, and average beam path (skin to tumour edge) was 7.3 ± 1.9cm. Eighty one percent of tumours were ≤ 0.3cm from an OAR. Of the 24 virtually simulated tumours to date, 6/8 lower, 6/8 mid, and 1/8 upper rectal tumours were targetable by MR-HIFU. Conclusions: This is the first virtual analysis to evaluate MR-HIFU HT targetability in primary rectal cancer. Results from this study will support MR-HIFU HT as an option to enhance the treatment of primary rectal cancer. Acknowledgments: This study has been funded by the Canadian Cancer Society. Patient & tumour characteristics. [Table: see text]

260: High Intensity Focused Ultrasound Combined with Endocrine Therapy in Treating High or Intermediate Risk Prostate Cancer

2006 ◽  
Vol 175 (4S) ◽  
pp. 86-86
Author(s):  
Makoto Sumitomo ◽  
Junichi Asakuma ◽  
Yasumasa Hanawa ◽  
Kazuhiko Nagakura ◽  
Masamichi Hayakawa
Keyword(s):  
Prostate Cancer ◽  
Endocrine Therapy ◽  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Intermediate Risk ◽  
Risk Prostate Cancer

1400: Early Clinical Experience Using High-Intensity Focused Ultrasound for the Treatment of Renal Tumours

2005 ◽  
Vol 173 (4S) ◽  
pp. 379-380
Author(s):  
James E. Kennedy ◽  
Rowland O. Illing ◽  
Feng Wu ◽  
Gail R. ter Haar ◽  
Rachel R. Phillips ◽  
...  
Keyword(s):  
Clinical Experience ◽  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Early Clinical Experience ◽  
Renal Tumours

Das Prostatakarzinom: aktuelle Diagnostik und Therapiestandard

Praxis ◽  
2016 ◽  
Vol 105 (16) ◽  
pp. 971-977
Author(s):  
Jan Brachlow ◽  
Martin Kälin ◽  
Marco Randazzo ◽  
Beat Förster ◽  
Hubert John
Keyword(s):  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Psa Test ◽  
Eine Hohe ◽  
Psa Screening ◽  
Sekundäre Hormontherapie

Zusammenfassung. Das Prostatakarzinom zeigt eine hohe Prävalenz und ist daher für die behandelnden Ärzte medizinisch, aber auch gesundheitspolitisch relevant. PSA-Screening senkt die karzinomspezifische Mortalität, ist jedoch aufgrund der hohen Prävalenz mit einer Überdiagnostik verbunden. Dies fordert im Gegenzug einen verantwortungsbewussten Umgang mit dem PSA-Test («smarter screening»). Durch die robotergestützte Prostatektomie steht eine Therapie mit geringer Morbidität zur Behandlung des lokalisierten Prostatakarzinoms zur Verfügung. Das fokale Behandlungskonzept der HIFU (high-intensity focused ultrasound) ist vielversprechend, jedoch noch klinisch experimentell und sollte im Rahmen von Studien angeboten werden. Die Behandlungsmöglichkeiten beim metastasierten Prostatakarzinom wurden entscheidend vervielfältigt. Chemotherapie und die sekundäre Hormontherapie werden voraussichtlich vermehrt in früheren Phasen der Krankheit eine Rolle spielen, wodurch die Therapie für den einzelnen Patienten immer komplexer wird und individuell angepasst werden muss.

Sign in / Sign up

Export Citation Format

Share Document